Salestools LogoSalestools
Salestools AI Agents
Solutions
Resources
Company
Pricing
Salestools Logo

Salestools

The #1 AI Agent for Sales teams and Go To Market teams. Sell more, faster, with less effort.

Product

  • AI Sales Agents
  • Intent Data
  • Technology Data
  • Visitor Tracking
  • Co-Pilot
  • Social Selling

Solutions

  • Customer Service
  • E-commerce
  • SaaS
  • Enterprise
  • Small Business

Resources

  • The Report
  • Documentation
  • API Reference
  • Help Center
  • Blog
  • Case Studies
  • Webinars

Company

  • About
  • Careers
  • Press
  • Contact
  • Partners

Our locations

  • New York, HQ
  • Bucharest, AI Research Lab
  • Zug, Switzerland

Β© 2026 Salestools. All rights reserved.

Data Terms & SecurityPrivacy PolicyTerms of ServiceAcceptable Use
All systems operational
Salestools LogoSalestools
Salestools AI Agents
Solutions
Resources
Company
Pricing
Back to Reports
Fundraising

Colossal Biosciences

Colossal Biosciences Raises $120M in Series

Austin, TXSeptember 27, 20252 min read
Employees
100+

Colossal Biosciences Raises $120M in Series


Colossal Biosciences has successfully raised $120M in a Series at a $800M valuation led by CIA In-Q-Tel, Breyer Capital.


Company Overview


Colossal Biosciences is a Biotech company headquartered in Austin, TX, founded in 2021 with 100+ employees.


Working on de-extinction of species including mammoths and dodos


Fundraising Details


  • Amount Raised: $120M
  • Round Type: Series
  • Valuation: $800M
  • Date: 2025-09-27
  • Investors: CIA In-Q-Tel, Breyer Capital

About Colossal Biosciences


Working on de-extinction of species including mammoths and dodos The company is positioned in the Biotech sector, serving a growing market with innovative solutions.


Key Information


  • Headquarters: Austin, TX
  • Founded: 2021
  • Team Size: 100+
  • Industry: Biotech

What This Means


This funding round demonstrates strong investor confidence in Colossal Biosciences's vision and execution. The capital will likely be used to:


  • Scale Operations: Expand the team and operational capacity
  • Product Development: Enhance existing products and develop new features
  • Market Expansion: Enter new markets and strengthen presence in existing ones
  • Technology Investment: Invest in infrastructure and technology capabilities

Industry Context


The Biotech sector continues to attract significant investment as companies innovate to meet evolving market demands. Colossal Biosciences's successful fundraising reflects the strong fundamentals and growth potential in this space.


Valuation Milestone


Reaching a $800M valuation marks an important milestone for Colossal Biosciences, positioning the company among notable players in the Biotech industry.


Looking Ahead


With this new capital, Colossal Biosciences is well-positioned to execute on its growth strategy and continue building innovative solutions in the Biotech space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.


This fundraising news was reported on 2025-09-27. For more information about Colossal Biosciences, visit their headquarters at Austin, TX.

Company Info

Headquarters
Austin, TX
Founded
2021
Team Size
100+

Topics

Fundraising(2912)Series(543)BiotechColossal Biosciences

Share

Related Reports

Fundraising
Tebra

Tebra Raises $250M Growth Financing | Healthcare Practice Management Platform

Healthcare practice management platform Tebra secures $250 million in growth financing led by Hildred Capital for AI-driven automation.

SalesTools Research
SalesTools Research
Jan 12, 2026
0 min readβ€’$250M
Fundraising
Harmattan AI

Harmattan AI Raises $200M Series B | Defense Tech Unicorn at $1.4B Valuation

French defense tech company Harmattan AI secures $200 million Series B led by Dassault Aviation, reaching unicorn status.

SalesTools Research
SalesTools Research
Jan 11, 2026
0 min readβ€’$200M
Fundraising
AirNexis Therapeutics

AirNexis Therapeutics Raises $200M Series A | Novel COPD Treatment

Biotech AirNexis Therapeutics emerges from stealth with $200 million Series A for dual PDE3/4 inhibitor COPD therapy.

SalesTools Research
SalesTools Research
Jan 11, 2026
0 min readβ€’$200M

Turn your sales ideas into reality today

Start your 14-day Pro trial today. No credit card required.

Start building for free